.png)
BMS Q4'25 Melanoma Highlights
- Oncofocus Team
- Feb 24
- 1 min read
Bristol Myers Squibb's Q4 2025 earnings call spotlighted key milestones for the Opdualag franchise in melanoma
📊 Blockbuster Status and US Dominance
Four years post-launch, Opdualag reached blockbuster status with 2025 global revenues of $1,185M, driven by $1,045M in the US. It has captured over 30% US market share, cementing its role as a standard-of-care option for metastatic melanoma. The ex-US market remains largely untapped with sales generating only $140M, constrained by restricted labeling and reimbursement barriers.
🎯 European Label Extension Filing
BMS has submitted a filing to the European Medicines Agency for label expansion to encompass advanced melanoma patients with PD-L1 expression ≥1% (presently approved solely for PD-L1 <1%). This application rests on the 4-year update from the Phase 2/3 RELATIVITY-047 trial, assessing Opdualag in first-line advanced melanoma. Compared to preliminary findings, long-term outcomes demonstrated enhanced overall survival (OS), evidenced by a reduced hazard ratio and confidence interval upper bound below 1. The safety profile exhibited stability, with merely numerical elevations in adverse event rates over time.
🛑 Pipeline Setbacks in Melanoma
The Phase 3 RELATIVITY-127 trial for subcutaneous Opdualag in first-line melanoma—originally slated for H2 2025 readout—was removed from BMS's pipeline, marking the second Phase 3 failure in melanoma after RELATIVITY-098 in the adjuvant setting. Without disclosed reasons, likely endpoint misses or limited commercial upside (post-adjuvant failure) drove this decision.
📝 Implications
Amid these Phase 3 setbacks, the EU filing represents BMS's critical push to broaden Opdualag's global melanoma share. If approved (decision expected in Q2 2026), it would unlock a major EU market currently inaccessible due to PD-L1 restrictions, potentially mirroring the growth trajectory in the US.
Comments